Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas - PubMed (original) (raw)
. 2010 May 1;70(9):3557-65.
doi: 10.1158/0008-5472.CAN-09-4674. Epub 2010 Apr 13.
Lara S Collier, Fausto J Rodriguez, Christina Tieu, Jon D Larson, Chandralekha Halder, Eric Mahlum, Thomas M Kollmeyer, Keiko Akagi, Gobinda Sarkar, David A Largaespada, Robert B Jenkins
Affiliations
- PMID: 20388773
- PMCID: PMC2862088
- DOI: 10.1158/0008-5472.CAN-09-4674
Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas
Aaron M Bender et al. Cancer Res. 2010.
Abstract
The Sleeping Beauty (SB) transposon system has been used as an insertional mutagenesis tool to identify novel cancer genes. To identify glioma-associated genes, we evaluated tumor formation in the brain tissue from 117 transgenic mice that had undergone constitutive SB-mediated transposition. Upon analysis, 21 samples (18%) contained neoplastic tissue with features of high-grade astrocytomas. These tumors expressed glial markers and were histologically similar to human glioma. Genomic DNA from SB-induced astrocytoma tissue was extracted and transposon insertion sites were identified. Insertions in the growth factor gene Csf1 were found in 13 of the 21 tumors (62%), clustered in introns 5 and 8. Using reverse transcription-PCR, we documented increased Csf1 RNAs in tumor versus adjacent normal tissue, with the identification of transposon-terminated Csf1 mRNAs in astrocytomas with SB insertions in intron 8. Analysis of human glioblastomas revealed increased levels of Csf1 RNA and protein. Together, these results indicate that SB-insertional mutagenesis can identify high-grade astrocytoma-associated genes and they imply an important role for CSF1 in the development of these tumors.
(c)2010 AACR.
Conflict of interest statement
Potential Conflict of Interest: None
Figures
Figure 1. SB-Induced Brain Tumors Display Characteristics of High Grade Astrocytomas
(A) Left: Low power image of large, SB-induced astrocytoma including mitotic figure (inset). Note invasive edge (black arrowheads). Right: Image depicting pseudopallisading necrosis (white arrowheads), a classic histologic feature of human GBM. (B, C, D,) A subset of tumor cells stain positive for glial markers GFAP (black arrowheads, B), S100 (Black arrowheads, C), and Olig2 (D).
Figure 2. Clustering of SB insertions at the Csf1 locus as well as elevated expression suggests a functional connection to pathogenesis of high grade astrocytomas
(A) SB insertions at the Csf1 locus cluster in the 5th and 8th introns and are largely oriented in the same direction as Csf1 transcription (arrows). Underlined insertions denote chimeric transcripts. Blue arrows indicate samples used for comparative PCR analysis in B. (B) qRT (above) and semi-quantitative (below) PCR analysis of primary murine GBM samples showing elevation of Csf1 transcript in tumor (T) vs. adjacent normal (N) tissue. Error bars represent standard deviation of fold-change. (C) Top: Neoplastic cells from mouse tumor 333 display immunohistochemical staining of Csf1 (arrowheads) and its receptor CSF1R (arrows) respectively. Bottom: In contrast, adjacent normal tissue from the same specimen did not show appreciable staining for either Csf1 or Csf1R.
Figure 3. Over-expression of CSF1 in human GBM
(A) Immunohistochemical staining showing CSF1 (Arrows, right) and CSF1R (Arrows, left) staining in human GBM tissue sections. (B) Western blot of whole cell lysates from normal (post-mortem) brain (N1-N5) as well as from primary human GBMs (T1-T15). Bars represent the ratio of CSF1 to GAPDH signal intensity. (C) qRT-PCR result showing elevated levels of CSF1 transcript in normal (n=5) vs. GBM (n=18) tissue (p-value generated using Wilcoxon rank-sum test). (D) Top: Dual label immunofluorescence images illustrating tumor cells (white arrows) expressing both CSF1 (Red) and the glial marker GFAP (Green). Bottom: Separate immunofluorescence experiment illustrating distinct CSF1 staining in (red) tumor cells (arrowheads) and CD45 staining in (green) infiltrating lymphoid/myeloid cells.
Similar articles
- Identification of Sleeping Beauty transposon insertions in solid tumors using linker-mediated PCR.
Janik CL, Starr TK. Janik CL, et al. J Vis Exp. 2013 Feb 1;(72):e50156. doi: 10.3791/50156. J Vis Exp. 2013. PMID: 23407503 Free PMC article. - Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality.
Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, Davies MN, Diers MD, Rodriguez FJ, Bender AM, Tieu C, Matise I, Dupuy AJ, Copeland NG, Jenkins NA, Hodgson JG, Weiss WA, Jenkins RB, Largaespada DA. Collier LS, et al. Cancer Res. 2009 Nov 1;69(21):8429-37. doi: 10.1158/0008-5472.CAN-09-1760. Epub 2009 Oct 20. Cancer Res. 2009. PMID: 19843846 Free PMC article. - Transposon mutagenesis of the mouse germline.
Carlson CM, Dupuy AJ, Fritz S, Roberg-Perez KJ, Fletcher CF, Largaespada DA. Carlson CM, et al. Genetics. 2003 Sep;165(1):243-56. doi: 10.1093/genetics/165.1.243. Genetics. 2003. PMID: 14504232 Free PMC article. - Sleeping beauty--a mouse model for all cancers?
Howell VM. Howell VM. Cancer Lett. 2012 Apr 1;317(1):1-8. doi: 10.1016/j.canlet.2011.11.006. Epub 2011 Nov 10. Cancer Lett. 2012. PMID: 22079740 Review. - [Advances in studies of Sleeping Beauty transposon].
Xie F, Gao B, Song CY, Chen GH. Xie F, et al. Yi Chuan. 2007 Jul;29(7):785-92. doi: 10.1360/yc-007-0785. Yi Chuan. 2007. PMID: 17646142 Review. Chinese.
Cited by
- Translational Models in Glioma Immunotherapy Research.
Ren AL, Wu JY, Lee SY, Lim M. Ren AL, et al. Curr Oncol. 2023 Jun 11;30(6):5704-5718. doi: 10.3390/curroncol30060428. Curr Oncol. 2023. PMID: 37366911 Free PMC article. Review. - Cancer ego-system in glioma: an iron-replenishing niche network systemically self-organized by cancer stem cells.
Tabu K, Taga T. Tabu K, et al. Inflamm Regen. 2022 Nov 30;42(1):54. doi: 10.1186/s41232-022-00240-8. Inflamm Regen. 2022. PMID: 36451253 Free PMC article. Review. - Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.
Franson A, McClellan BL, Varela ML, Comba A, Syed MF, Banerjee K, Zhu Z, Gonzalez N, Candolfi M, Lowenstein P, Castro MG. Franson A, et al. Front Med (Lausanne). 2022 Sep 14;9:966458. doi: 10.3389/fmed.2022.966458. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36186781 Free PMC article. Review. - IL-10 in glioma.
Widodo SS, Dinevska M, Furst LM, Stylli SS, Mantamadiotis T. Widodo SS, et al. Br J Cancer. 2021 Nov;125(11):1466-1476. doi: 10.1038/s41416-021-01515-6. Epub 2021 Aug 4. Br J Cancer. 2021. PMID: 34349251 Free PMC article. Review. - Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.
Alghamri MS, McClellan BL, Hartlage CS, Haase S, Faisal SM, Thalla R, Dabaja A, Banerjee K, Carney SV, Mujeeb AA, Olin MR, Moon JJ, Schwendeman A, Lowenstein PR, Castro MG. Alghamri MS, et al. Front Pharmacol. 2021 May 18;12:680021. doi: 10.3389/fphar.2021.680021. eCollection 2021. Front Pharmacol. 2021. PMID: 34084145 Free PMC article. Review.
References
- CBTRUS Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Published by the Central Brain Tumor Registry of the United States. 2005
- Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res. 2006;12:5288–5297. - PubMed
- Liu D, Yang X, Yang D, Songyang Z. Genetic screens in mammalian cells by enhanced retroviral mutagens. Oncogene. 2000;19:5964–5972. - PubMed
- Plasterk RH, Izsvak Z, Ivics Z. Resident aliens: the Tc1/mariner superfamily of transposable elements. Trends Genet. 1999;15:326–332. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA113636-05/CA/NCI NIH HHS/United States
- R01CA113636/CA/NCI NIH HHS/United States
- R01 CA113636-04/CA/NCI NIH HHS/United States
- K01CA122183/CA/NCI NIH HHS/United States
- T32 CA009138/CA/NCI NIH HHS/United States
- R01 CA113636-01A1/CA/NCI NIH HHS/United States
- R01 CA113636-02/CA/NCI NIH HHS/United States
- R01 CA113636/CA/NCI NIH HHS/United States
- R01 CA113636-03/CA/NCI NIH HHS/United States
- K01 CA122183/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous